CO4520283A1 - Agentes antivirales - Google Patents
Agentes antiviralesInfo
- Publication number
- CO4520283A1 CO4520283A1 CO94047671A CO94047671A CO4520283A1 CO 4520283 A1 CO4520283 A1 CO 4520283A1 CO 94047671 A CO94047671 A CO 94047671A CO 94047671 A CO94047671 A CO 94047671A CO 4520283 A1 CO4520283 A1 CO 4520283A1
- Authority
- CO
- Colombia
- Prior art keywords
- flavine
- derivative
- treatment
- diseases caused
- virosic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
1. EL USO DE UNA FLAVINA, UN DERIVADO DE LA MIS- MA, O DE UNA MEZCLA QUE COMPRENDE DOS O MAS DE ELLAS PARA LA FABRICACION DE UN MEDICAMENTO DESTI- NADO AL TRATAMIENTO POR PROFILAXIS O TERAPIA DE ENFERMEDADES CAUSADAS POR INFECCION VIROSICA. 11. UNA FLAVINA O DERIVADO DE FLAVINA PARA USO EN LA FABRICACION DE UN MEDICAMENTO UTIL EN EL TRATA- MIENTO POR PORFILAXIS O TERAPIA DE ENFERMEDADES CAUSADAS POR INFECCION VIROSICA. 13. UNA COMPOSICION FARMACEUTICA PARA EL TRATA- MIENTO POR PROFILAXIS O TERAPIA DE ENFERMEDADES CAUSADAS POR INFECCION VIROSICA, CARACTERIZANDOSE LA COMPOSICION PORQUE COMPRENDE UNA FLAVINA O DE- RIVADO DE FLAVINA. 20. UN RECEPTACULO PARA CONTENCION FARMACEUTICA INMEDIATA PREVIA A LA ADMINISTRACION, SIENDO MANI- PULABLE DICHO RECEPTACULO EN UN PROCESO DE ADMI- NISTRACION DE MEDICAMENTOS POR FACULTATIVOS MEDI- COS Y CONTENIENDO UNA FLAVINA O DERIVADO DE FLAVI- NA PARA SU DESCARGA DEL RECEPTACULO A UN PACIENTE O A UN DISPOSITIVO DE UNA REPRESENTACION DE INS- TRUCCIONES PARA EL USO DE LA FLAVINA O DEL DERIVA- DO DE FLAVINA COMO MEDICAMENTO EN EL TRATAMIENTO POR PROFILAXIS O TERAPIA DE ENFERMEDADES CAUSADAS POR INFECCIONES VIROSICAS. 21. LA COMBINACION DE.: (a) UNA FLAVINA O UN DERIVADO DE FLAVINA FORMULADO PARA USO FARMACEUTICO, Y (b) INSTRUCCIONES DE USO DE DICHA FLAVINA O DERI- VADO DE FLAVINA FORMULADO PARA LA FABRICACION DE UN MEDICAMENTO DESTINADO AL TRATAMIENTO POR TERA- PIA O PROFILAXIS DE ENFERMEDADES CAUSADAS POR IN- FECCIONES VIROSICAS O PARA SU USO EN DICHO TRATA- MIENTO. 24. UN PROCEDIMIENTO PARA LA PREPARACION DE UN ME- DICAMENTO PARA EL USO EN EL TRATAMIENTO DE LAS IN- FECCIONES VIROSICAS, PROCEDIMIENTOS QUE COMPRENDE LA FORMULACION DE UNA FLAVINA TAL COMO RIBOFLAVI- NA O UN DERIVADO DE LA MISMA, PARA USO ANTIVIROSI- CO.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB939321558A GB9321558D0 (en) | 1993-10-19 | 1993-10-19 | Anti-viral agents |
Publications (1)
Publication Number | Publication Date |
---|---|
CO4520283A1 true CO4520283A1 (es) | 1997-10-15 |
Family
ID=10743784
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO94047671A CO4520283A1 (es) | 1993-10-19 | 1994-10-19 | Agentes antivirales |
Country Status (26)
Country | Link |
---|---|
EP (1) | EP0739208A1 (es) |
JP (1) | JPH09505804A (es) |
CN (1) | CN1140992A (es) |
AP (1) | AP620A (es) |
AU (1) | AU7943794A (es) |
BG (1) | BG100599A (es) |
BR (1) | BR9407862A (es) |
CA (2) | CA2123825A1 (es) |
CO (1) | CO4520283A1 (es) |
CZ (1) | CZ113796A3 (es) |
EE (1) | EE9600057A (es) |
GB (2) | GB9321558D0 (es) |
HR (1) | HRP940688A2 (es) |
HU (1) | HUT76322A (es) |
IL (1) | IL111338A0 (es) |
JO (1) | JO1866B1 (es) |
MA (1) | MA23356A1 (es) |
MD (1) | MD960168A (es) |
NO (1) | NO961547L (es) |
OA (1) | OA10579A (es) |
PE (1) | PE5596A1 (es) |
PL (1) | PL314008A1 (es) |
SK (1) | SK50696A3 (es) |
UY (1) | UY23844A1 (es) |
WO (1) | WO1995011028A1 (es) |
ZA (1) | ZA948191B (es) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07188052A (ja) * | 1993-12-27 | 1995-07-25 | Sanwa Kagaku Kenkyusho Co Ltd | インターフェロン用作用効果増強剤及び該増強剤とインターフェロンとを含有する抗ウイルス活性増強組成物 |
US5756479A (en) * | 1994-12-29 | 1998-05-26 | Research Development Foundation | Flavin adenine dinucleotide analogue inhibitors of monoamine oxidase |
US9044523B2 (en) | 2000-06-15 | 2015-06-02 | Terumo Bct, Inc. | Reduction of contaminants in blood and blood products using photosensitizers and peak wavelengths of light |
AU2003299486A1 (en) * | 2002-05-10 | 2004-06-03 | The Ohio State University | Flavin n-oxides: new anti-cancer agents and pathogen eradication agents |
ITTO20020622A1 (it) | 2002-07-16 | 2004-01-16 | Dayco Europe Srl | Gruppo integrato puleggia-smorzatore torsionale |
US20060293335A1 (en) * | 2002-08-02 | 2006-12-28 | Qishou Xu | Riboflavin derivative and its manufacture and uses |
EP2545788A1 (de) * | 2011-07-13 | 2013-01-16 | Martin Hulliger | Diätisches Mehrkomponentensystem |
JP2018131410A (ja) * | 2017-02-15 | 2018-08-23 | ヒノキ新薬株式会社 | カスパーゼ−3阻害剤とその用途 |
CU20200039A7 (es) * | 2017-10-24 | 2021-03-11 | Lunella Biotech Inc | Mitoflavoscinas: la fijación como objetivo de enzimas que contienen flavina elimina células madre cancerosas (cscs) al inhibir la respiración mitocrondrial |
US20220257550A1 (en) * | 2019-07-09 | 2022-08-18 | Dsm Ip Assets B.V. | Reducing the viral activity of elafibranor with riboflavin or dha |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4219545A (en) * | 1979-03-23 | 1980-08-26 | Collins Calvin E | Treatment of infectious keratoconjunctivitis in animals |
US4264601A (en) * | 1979-06-12 | 1981-04-28 | The Board Of Regents Of The University Of Oklahoma | Antihypertensive agents and their use in treatment of hypertension |
US4500524A (en) * | 1982-09-15 | 1985-02-19 | Trustees Of Boston University | Tranquilizing and reducing or preventing seizures |
WO1991002529A2 (en) * | 1989-08-14 | 1991-03-07 | John Bennett Kizer | Product and method for killing abnormal vertebrate cells |
JP2727471B2 (ja) * | 1989-09-14 | 1998-03-11 | 三井農林株式会社 | インフルエンザウィルス感染予防剤 |
US5192264A (en) * | 1989-10-06 | 1993-03-09 | The Beth Israel Hospital Association | Methods and apparatus for treating disease states using oxidized lipoproteins |
US5217716A (en) * | 1990-07-18 | 1993-06-08 | The Beth Israel Hospital Association | Method for treating viral infections using oxidized lipoproteins |
FR2674753B1 (fr) * | 1991-04-02 | 1995-03-10 | Jean Berque | Nouvelles indications therapeutiques, en particulier pour le traitement du sida, d'un medicament deja existant et fabrique a partir d'une molecule denuee de contre-indications et d'effets indesirables. |
NZ244270A (en) * | 1991-09-13 | 1995-07-26 | Eisai Co Ltd | Injectable composition comprising riboflavin |
WO1993010784A1 (en) * | 1991-11-25 | 1993-06-10 | University Of Michigan | Therapeutic composition and method for preventing reperfusion injury |
JP3073309B2 (ja) * | 1992-03-27 | 2000-08-07 | 雪印乳業株式会社 | シアル酸結合5−デアザフラビン系化合物 |
-
1993
- 1993-10-19 GB GB939321558A patent/GB9321558D0/en active Pending
-
1994
- 1994-01-19 JO JO19941866A patent/JO1866B1/en active
- 1994-05-18 CA CA2123825A patent/CA2123825A1/en active Pending
- 1994-10-18 MA MA23679A patent/MA23356A1/fr unknown
- 1994-10-19 PE PE1994253128A patent/PE5596A1/es not_active Application Discontinuation
- 1994-10-19 GB GB9421099A patent/GB2283913A/en not_active Withdrawn
- 1994-10-19 HR HR9321558.0A patent/HRP940688A2/hr not_active Application Discontinuation
- 1994-10-19 EE EE9600057A patent/EE9600057A/xx unknown
- 1994-10-19 EP EP94930272A patent/EP0739208A1/en not_active Withdrawn
- 1994-10-19 IL IL11133894A patent/IL111338A0/xx unknown
- 1994-10-19 CZ CZ961137A patent/CZ113796A3/cs unknown
- 1994-10-19 UY UY23844A patent/UY23844A1/es unknown
- 1994-10-19 WO PCT/GB1994/002292 patent/WO1995011028A1/en not_active Application Discontinuation
- 1994-10-19 HU HU9601006A patent/HUT76322A/hu unknown
- 1994-10-19 AU AU79437/94A patent/AU7943794A/en not_active Abandoned
- 1994-10-19 SK SK506-96A patent/SK50696A3/sk unknown
- 1994-10-19 ZA ZA948191A patent/ZA948191B/xx unknown
- 1994-10-19 AP APAP/P/1994/000695A patent/AP620A/en active
- 1994-10-19 JP JP7511518A patent/JPH09505804A/ja active Pending
- 1994-10-19 CO CO94047671A patent/CO4520283A1/es unknown
- 1994-10-19 PL PL94314008A patent/PL314008A1/xx unknown
- 1994-10-19 CA CA002174552A patent/CA2174552A1/en not_active Abandoned
- 1994-10-19 CN CN94194350A patent/CN1140992A/zh active Pending
- 1994-10-19 BR BR9407862A patent/BR9407862A/pt not_active Application Discontinuation
-
1996
- 1996-04-18 NO NO961547A patent/NO961547L/no unknown
- 1996-04-18 OA OA60815A patent/OA10579A/en unknown
- 1996-05-17 BG BG100599A patent/BG100599A/xx unknown
- 1996-05-17 MD MD96-0168A patent/MD960168A/ro not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CA2174552A1 (en) | 1995-04-27 |
CN1140992A (zh) | 1997-01-22 |
WO1995011028A1 (en) | 1995-04-27 |
CA2123825A1 (en) | 1995-04-20 |
BG100599A (en) | 1997-02-28 |
SK50696A3 (en) | 1997-01-08 |
IL111338A0 (en) | 1994-12-29 |
HRP940688A2 (en) | 1997-04-30 |
GB9321558D0 (en) | 1993-12-08 |
ZA948191B (en) | 1995-06-08 |
GB2283913A (en) | 1995-05-24 |
AU7943794A (en) | 1995-05-08 |
AP620A (en) | 1997-10-14 |
EE9600057A (et) | 1996-10-15 |
JPH09505804A (ja) | 1997-06-10 |
PL314008A1 (en) | 1996-08-05 |
JO1866B1 (en) | 1995-12-27 |
HUT76322A (en) | 1997-08-28 |
CZ113796A3 (en) | 1996-11-13 |
BR9407862A (pt) | 1997-05-20 |
GB9421099D0 (en) | 1994-12-07 |
PE5596A1 (es) | 1996-04-18 |
MA23356A1 (fr) | 1995-07-01 |
HU9601006D0 (en) | 1996-06-28 |
NO961547L (no) | 1996-06-19 |
AP9400695A0 (en) | 1995-01-31 |
NO961547D0 (no) | 1996-04-18 |
UY23844A1 (es) | 1995-03-28 |
OA10579A (en) | 2002-06-19 |
EP0739208A1 (en) | 1996-10-30 |
MD960168A (ro) | 1998-04-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU94002475A (ru) | Фармацевтическая композиция и ее применение для лечения вирусных инфекций | |
MY117892A (en) | Therapeutic compounds | |
MY104575A (en) | Therapeutic nucleosides. | |
ES2062392T3 (es) | Medicamentos que comprenden salmeterol y fluticasona. | |
UA29429C2 (uk) | Фармацевтична композиція для лікування вірусних інфекцій, спосіб отримання композиції, спосіб лікування або профілактики віл-інфекції у людини | |
HU9300636D0 (en) | Medical preparatives, method for producing them and their applications as analgetic and/or febrifuge in human and veterinary medicine | |
DE69132688D1 (de) | Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin | |
MY104043A (en) | Therapeutic nucleosides. | |
BR9406893A (pt) | Emprego de nona- e decapeptideos para a preparação de um medicamento para o combate da aids | |
AR019853A1 (es) | Derivado del acido 3-aril-2-hidroxipropionico, proceso e intermediario para su preparacion, formulaciones farmaceuticas, uso de dicho compuesto en laelaboracion de un medicamento, metodo para la profilaxis y/o tratamiento de trastornos clinicos asociados con la resistencia a la insulina, y formulaci | |
AR004510A1 (es) | Composiciones que comprenden amoxicilina y clavulanato, procedimientos para su preparacion y el uso de las composiciones para la fabricacion de unmedicamento | |
CO4520283A1 (es) | Agentes antivirales | |
IT1170214B (it) | Composizione farmaceutica per la cura delle arteriopatie periferiche | |
HUP9901890A2 (hu) | Gyógyszer és eljárás szervezet gyógyszeres kezelésére | |
DE60031016D1 (de) | Verwendung von Antiseptika zur Herstellung von Arzneimitteln zur Prophylaxe und Behandlung von Entzündungen im Korperinneren des Menschen | |
MX9805441A (es) | Compuestos terapeuticos. | |
ES8400742A1 (es) | Procedimiento de preparacion de las dibenzooxepinas sustituidas y de sus sales de adicion con un acido mineral u organi-co. | |
DK166715B1 (da) | Farmaceutiske produkt og anvendelse af dette til fremstilling af et kombinationspraeparat til behandling af virusinfektioner | |
PT777669E (pt) | Utilizacao de succinato de 4-(2-amino-6-(ciclopropilamino)-9h-purin-9-il)-2-ciclopenteno-1-metanol como agente antiviral | |
FR2694693B1 (fr) | Composition pharmaceutique à base de flavopéréirine et son utilisation dans un traitement contre le virus VIH. | |
AR006202A1 (es) | Usos de antagonista ige para preparar un medicamento util para el tratamiento de las enfermedades alergicas y composiciones que los contiene | |
KR100227125B1 (ko) | 미포자충감염을치료하기위한벤즈이미다졸구충제의용도 | |
ES2148268T3 (es) | Composicion farmaceutica para prevenir o tratar fracturas de huesos. | |
MX9303985A (es) | Nucleosidos terapeuticos. | |
DE69033252D1 (de) | Therapeutische nukleoside |